Mitochondrial serine protease HtrA2/Omi as a potential therapeutic target

Md Shenuarin Bhuiyan, Koji Fukunaga

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)


Deregulation of apoptosis has been shown to contribute to the development of many diseases, including ischemia/reperfusion injury of organs, different types of cancer formation, as well as neurodegenerative and autoimmune disorders. Recently, the mitochondrial serine protease High temperature requirement A2 (HtrA2)/Omi has drawn attention as it played pivotal role in different pathological conditions. We critically discussed the rationale for therapeutically targeting HtrA2 signaling in pathological conditions and explore the molecular mechanisms of HtrA2 inhibition as a novel therapeutic strategy. The precise mode of action and importance of HtrA2 in mitochondrial quality control as well as in apoptosis in mammalian cells has been recently studied through biochemical, structural and genetic studies. This review introduces HrtA2 from its molecular origins, discusses its modulation and potential as a novel drug target, and considers future therapeutic perspectives.

Original languageEnglish
Pages (from-to)372-383
Number of pages12
JournalCurrent Drug Targets
Issue number4
Publication statusPublished - 2009 May 18


  • Apoptosis
  • Caspases
  • HtrA2
  • Inhibitor of apoptosis proteins
  • Mitochondria

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'Mitochondrial serine protease HtrA2/Omi as a potential therapeutic target'. Together they form a unique fingerprint.

Cite this